Patent US4438642A successfully refreshed from Google Patents.
Patent US4542152A successfully refreshed from Google Patents.
US4542152A
Expired / Lapsed
US
⏱️ 0.0 years remaining
5-[Phenylsulfonyl(or sulfinyl)]thiophene-2-sulfonamides for the topical treatment of elevated intraocular pressure
Assignee: Merck and Co Inc
•
Filing: 1983-06-20
•
Granted: 1985-09-17
•
Expires: 2003-06-20
Abstract
Abstract 5-[Phenylsulfonyl(or sulfinyl)]thiophene-2-sulfonamides are useful for the topical treatment of elevated intraocular pressure. Ophthalmic compositions including drops and inserts are disclosed.
Inventors
- 👤 Kenneth L. Shepard
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-06 10:49
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/33; A61K31/38
Claims Analysis
Total Claims: 11
Claim 1
Independent Claim
31 words
An ophthalmic composition for the topical treatment of glaucoma and ocular hypertension comprising a solid water soluble polymer and from 0.1 to 35% by weight of the carbonic anhydrase inhibitor 5-[(4-hydroxyphenyl)sulfonyl]thiophene-2-sulfonamide.
Claim 2
Dependent Claim
31 words
An ophthalmic composition for the topical treatment of glaucoma and ocular hypertension comprising a solid water soluble polymer and from 0.1 to 35% by weight of the carbonic anhydrase inhibitor 5-[(4-hydroxyphenyl)sulfonyl]thiophene-2-sulfonamide.
Claim 3
Dependent Claim
18 words
The composition of claim 1 which comprises from 0.25 to 5% by weight of the carbonic anhydrase inhibitor.
Claim 4
Dependent Claim
15 words
The composition of claim 1 wherein the solid polymer is hydroxypropyl cellulose or polyvinyl alcohol.
Claim 5
Independent Claim
31 words
A method for treating elevated intraocular pressure which comprises topically applying to an eye in need of such treatment, an effective intraocular pressure lowering amount of the carbonic anhydrase inhibitor, 5-[(4-hydroxyphenyl)sulfonyl]thiophene-2-sulfonamide.
Claim 6
Independent Claim
31 words
A method for treating elevated intraocular pressure which comprises topically applying to an eye in need of such treatment, an effective intraocular pressure lowering amount of the carbonic anhydrase inhibitor, 5-[(4-hydroxyphenyl)sulfonyl]thiophene-2-sulfonamide.
Claim 7
Dependent Claim
17 words
The method according to claim 4 wherein the carbonic anhydrase inhibitor is administered in a polymeric insert.
Claim 8
Dependent Claim
21 words
The method according to claim 5 where said insert comprises from 0.01 to 35% by weight of the carbonic anhydrase inhibitor.
Claim 9
Dependent Claim
14 words
The method according to claim 5 wherein the polymer is hydroxypropylcellulose or polyvinyl alcohol.
Claim 10
Dependent Claim
17 words
The method according to claim 4 wherein the carbonic anhydrase inhibitor is administered in an ointment base.
Claim 11
Dependent Claim
17 words
The method according to claim 4 wherein the carbonic anhydrase inhibitor is administered in a liquid vehicle.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1988-09-16 | 1989-03-18 | 1989-09-17 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1992-09-16 | 1993-03-18 | 1993-09-17 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1996-09-16 | 1997-03-18 | 1997-09-17 | $7700.00 | Window Closed / Lapsed |